SCHEMBL4427375

SCHEMBL4427375

Oc1ccc(CNCc2ccccc2)cc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD4 P21917 1/20 0.59
BCHE P06276 2/20 0.59
PKM P14618 1/20 0.59
MEN1 O00255 3/20 0.58
KMT2A Q03164 3/20 0.58
TDP1 Q9NUW8 1/20 0.58
HDAC8 Q9BY41 1/20 0.55
HDAC6 Q9UBN7 1/20 0.55
FNTA P49354 1/20 0.54
FNTB P49356 1/20 0.54
THRB P10828 2/20 0.53
MAPT P10636 2/20 0.53
KDM4E B2RXH2 1/20 0.53
ALDH1A1 P00352 1/20 0.53
ALOX12 P18054 1/20 0.53
CA1 P00915 1/20 0.53
CA2 P00918 1/20 0.53
IDO1 P14902 1/20 0.52
MAOA P21397 1/20 0.52
TRPV1 Q8NER1 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6277988 0.90 CA2 (0.61) DRD4BCHEMEN1KMT2ATHRB
SCHEMBL6540019 0.88 NR1H2 (0.52) DRD4BCHEPKMMEN1KMT2A
SCHEMBL10054993 0.87 MEN1 (0.74) BCHEPKMMEN1KMT2ATDP1
SCHEMBL580289 0.86 BCHE (0.77) DRD4BCHEMEN1KMT2ATDP1
SCHEMBL3695539 0.86 BCHE (0.77) DRD4BCHEMEN1KMT2ATDP1
SCHEMBL6541651 0.85 CA1 (0.63) DRD4BCHEPKMHDAC8HDAC6
SCHEMBL1654 0.84 MEN1 (0.78) BCHEPKMMEN1KMT2ATDP1
Benzene SCHEMBL11697595 0.84 MEN1 (0.78) BCHEPKMMEN1KMT2ATDP1
SCHEMBL5799878 0.84 MEN1 (0.78) BCHEPKMMEN1KMT2ATDP1
Hydrochloric Acid SCHEMBL9332806 0.84 GAA (0.78) DRD4BCHEMEN1KMT2ATDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3938356-B1 PROCESS FOR THE PRODUCTION OF A POLYBENZOXAZINE MONOMER ARIANEGROUP SAS (FR) 2024-09-18 EP disclosed
US-12065415-B2 Process for the production of a polybenzoxazine monomer ARIANEGROUP SAS (FR) 2024-08-20 US disclosed
US-20230192904-A1 BIFUNCTIONAL CHIMERIC MOLECULES FOR LABELING OF KINASES WITH TARGET BINDING MOIETIES AND METHODS OF USE THEREOF THE BROAD INSTITUTE, INC. 2023-06-22 US disclosed
US-20220177437-A1 PROCESS FOR THE PRODUCTION OF A POLYBENZOXAZINE MONOMER ECOLE NATIONALE SUPÉRIEURE DE CHIMIE DE MONTPELLIER (FR) 2022-06-09 US disclosed
EP-3938356-A1 PROCESS FOR THE PRODUCTION OF A POLYBENZOXAZINE MONOMER ArianeGroup SAS (FR) 2022-01-19 EP disclosed
WO-2020188182-A1 PROCESS FOR THE PRODUCTION OF A POLYBENZOXAZINE MONOMER ARIANEGROUP SAS (FR) 2020-09-24 WO disclosed
CN-104961672-B A kind of synthetic method of the tartrate of N (4 luorobenzyl) N (base of 1 methyl piperidine 4) N ' (4 isobutoxy benzyl) urea 沈阳药科大学 2017-10-20 CN disclosed
EP-2822941-B1 BENZODIOXANES IN COMBINATION WITH STATINS FOR INHIBITING LEUKOTRIENE PRODUCTION BOEHRINGER INGELHEIM INT (DE) 2017-05-10 EP disclosed
CN-104961672-A Synthetic method of tartrate of N-(4-fluorobenzyl)-N-(1-methylpiperidine-4-yl)-N'-(4-isobutoxybenzyl)urea UNIV SHENYANG PHARMACEUTICAL 2015-10-07 CN disclosed
EP-2336125-A1 Thiazolopyridin-2-yloxy-phenyl and thiazolopyrazin-2-yloxy-phenyl amines as modulators of leukotriene A4 hydrolase Janssen Pharmaceutica N.V. (BE) 2011-06-22 EP disclosed
EP-1384720-A1 Process for drying paroxetine hydrochloride SUMIKA FINE CHEMICALS Co., Ltd. (JP) 2004-01-28 EP disclosed
EP-1384711-A1 Optical resolution of a piperidine derivative SUMIKA FINE CHEMICALS Co., Ltd. (JP) 2004-01-28 EP disclosed
US-6610851-B1 1-tert-butoxycarbonyl-4-(4-fluorophenyl)-3-((3,4-methylene dioxyphenyl)oxymethyl)piperidine; reacting 4-(4-fluorophenyl)-3-hydroxymethylpiperidine with di-tert-butyl dicarbonate to form the carbamate; 3,4-methylenedioxyphenol SUMIKA FINE CHEMICALS CO., LTD. (JP) 2003-08-26 US disclosed
US-20030144519-A1 Process for preparing a piperidine derivative SUMIKA FINE CHEMICALS CO., LTD. 2003-07-31 US disclosed
US-6476227-B1 Piperidine derivative and process for preparing the same SUMIKA FINE CHEMICALS CO., LTD. (JP) 2002-11-05 US disclosed
EP-1124802-A1 PROCESS FOR PRODUCING 4-ARYLPIPERIDINE-3-CARBINOLS AND RELATED COMPOUNDS Synthon B.V. (NL) 2001-08-22 EP disclosed
WO-2000026187-A1 PROCESS FOR PRODUCING 4-ARYLPIPERIDINE-3-CARBINOLS AND RELATED COMPOUNDS SYNTHON B.V. (NL) 2000-05-11 WO disclosed
US-5948914-A PREPARING 4-(4-FLUOROPHENYL)-3-HYDROXYMETHYLPIPERIDINE BY OPTICALLY RESOLVING WITH O-CHLOROTARTRANILIC ACID; CHEMICAL INTERMEDIATE FOR DRUGS SUMIKA FINE CHEMICALS CO., LTD. (JP) 1999-09-07 US disclosed
EP-0812827-A1 Piperidine derivative as intermediates for the preparation of paroxetine and process for their preparation SUMIKA FINE CHEMICALS Co., Ltd. (JP) 1997-12-17 EP disclosed
US-5142052-A Cationic effect-driven carbinol/amine reaction LABORATOIRES SYNTEX (FR) 1992-08-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220177437-A1 PROCESS FOR THE PRODUCTION OF A POLYBENZOXAZINE MONOMER WIZ, PCBP1, TERB1 DRD4 2080/4885BCHE 2256/4885PKM 1320/4885
US-12065415-B2 Process for the production of a polybenzoxazine monomer WIZ, PCBP1, TERB1 DRD4 2080/4885BCHE 2256/4885PKM 1320/4885
US-20030144519-A1 Process for preparing a piperidine derivative TPH1, TPH2, HTR7 DRD4 8/4885BCHE 1046/4885PKM 303/4885
US-20230192904-A1 BIFUNCTIONAL CHIMERIC MOLECULES FOR LABELING OF KINASES WITH TARGET BINDING MOIETIES AND METHODS OF USE THEREOF ERBB2, ACP1, TK1 DRD4 4866/4885BCHE 2641/4885PKM 1041/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.